03:24 AM EDT, 10/26/2026 (MT Newswires) -- GSK (GSK.L) reported a sustained 12-month clinical complete response from the phase 2 Azur-1 trial of Jemperli, or dostarlimab, as a monotherapy for the treatment of adults with stage 2 and 3 microsatellite instability-high/mismatch repair deficient locally advanced rectal cancer. The British drugmaker said Monday that the safety profile of the drug in the trial was in line with the established profile across solid tumors. GSK is planning to present the positive interim results at the European Society for Medical Oncology Congress. Jemperli is under review by the US Food and Drug Administration.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.